Oxford, UK – 29 November 2013. OGT, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a free whitepaper titled ‘The importance of enrichment assay choice and optimisation for confident variant detection.’ The paper investigates the main strategies employed to optimise target enrichment for next generation sequencing (NGS) assays, assisting researchers to make informed decisions when designing studies.
The choice of target enrichment methodology can have a dramatic effect on the ability to confidently call each variant with no false negatives or positives. The whitepaper by OGT examines the impact of enrichment assay choice, comparing and contrasting hybridisation and amplicon approaches while considering factors such as target size, accuracy, cost and speed. The paper also addresses the potential sources of bias and error in enrichment assays, giving the reader a truly comprehensive overview of the subject.
Researchers can overcome the challenge of enrichment assay design with the use of an expert service provider. OGT’s Genefficiency NGS Services encompass an Expert Bait Design workflow that significantly improves the uniformity of target sequence enrichment, increasing sensitivity and accuracy of variant detection across the entire region. In addition, all results are provided in the unique Genefficiency NGS Variant Analysis Report that provides the freedom to interrogate the fully annotated data, without the need for local bioinformatics resource.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
Powerful, flexible and easy-to-use analysis solution gets the most out of NGS data, helping researchers effortlessly translate cumbersome NGS data into meaningful results.Read
New SureSeq myPanel™ NGS Custom Cancer Panel content covers a wider range of cancer types with excellent coverage uniformity for confident results.Read